Details of Drug Interaction

Details of Drug-Drug Interaction

 Drug General Information (ID: DDIASH7NF9)
  Drug Name Succinylcholine Drug Info Echothiophate (ophthalmic) Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Analgesics Ophthalmic Glaucoma Agents
  Structure

 Mechanism of Succinylcholine-Echothiophate (ophthalmic) Interaction (Severity Level: Moderate)
     Antagonize the effect of cholinergic agents Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Succinylcholine Echothiophate (ophthalmic)
      Mechanism Anticholinergic effects
Muscarinic acetylcholine receptor  Antagonist 		Cholinergic effects
Acetylcholinesterase  Inhibitor
      Key Mechanism Factor 1
Factor Name Muscarinic acetylcholine receptor M Structure Sequence
Protein Family G-protein coupled receptor 1 family
Protein Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
    Click to Show/Hide
      Key Mechanism Factor 2
Factor Name Acetylcholinesterase
×
Structure Sequence
MRPPQCLLHTPSLASPLLLLLLWLLGGGVGAEGREDAELLVTVRGGRLRGIRLKTPGGPVSAFLGIPFAEPPMGPRRFLPPEPKQPWSGVVDATTFQSVCYQYVDTLYPGFEGTEMWNPNRELSEDCLYLNVWTPYPRPTSPTPVLVWIYGGGFYSGASSLDVYDGRFLVQAERTVLVSMNYRVGAFGFLALPGSREAPGNVGLLDQRLALQWVQENVAAFGGDPTSVTLFGESAGAASVGMHLLSPPSRGLFHRAVLQSGAPNGPWATVGMGEARRRATQLAHLVGCPPGGTGGNDTELVACLRTRPAQVLVNHEWHVLPQESVFRFSFVPVVDGDFLSDTPEALINAGDFHGLQVLVGVVKDEGSYFLVYGAPGFSKDNESLISRAEFLAGVRVGVPQVSDLAAEAVVLHYTDWLHPEDPARLREALSDVVGDHNVVCPVAQLAGRLAAQGARVYAYVFEHRASTLSWPLWMGVPHGYEIEFIFGIPLDPSRNYTAEEKIFAQRLMRYWANFARTGDPNEPRDPKAPQWPPYTAGAQQYVSLDLRPLEVRRGLRAQACAFWNRFLPKLLSATDTLDEAERQWKAEFHRWSSYMVHWKNQFDHYSKQDRCSDL
Gene Name ACHE
Uniprot ID ACES_HUMAN
KEGG Pathway hsa:43
Protein Family Type-B carboxylesterase/lipase family
Protein Function
Hydrolyzes rapidly the acetylcholine neurotransmitter released into the synaptic cleft allowing to terminate the signal transduction at the neuromuscular junction. Role in neuronal apoptosis.
    Click to Show/Hide
      Mechanism Description
  • Antagonize the effect of Echothiophate (ophthalmic) when combined with Succinylcholine 

Recommended Action
      Management This combination should be avoided and a neuromuscular blocker other than succinylcholine should be considered in patients receiving chronic echothiophate therapy. If succinylcholine must be used, patients should be closely monitored for prolonged neuromuscular blocking effects. Some authorities recommend that echothiophate ophthalmic drops should be discontinued several months prior to administration of succinylcholine and/or consideration should be given to using a reduced dose of succinylcholine.

References
1 Cavallaro RJ, Krumperman LW, Kugler F "Effect of echothiophate therapy on the metabolism of succinylcholine in man." Anesth Analg 47 (1968): 570-4. [PMID: 5691696]
2 Cohen PJ, Reynolds RC, Naidl J "A simple test for abnormal pseudocholinesterase." Anesthesiology 32 (1970): 281-2. [PMID: 5412891]
3 Eilderton TE, farmati O, Zsigmond EK "Reduction in plasma cholinesterase levels after prolonged administration of echothiophate iodide eyedrops." Can Anaesth Soc J 15 (1968): 291-6. [PMID: 5658433]